421 related articles for article (PubMed ID: 25168947)
41. Evaluation of the Use of Low-Dose 4-Factor Prothrombin Complex Concentrate in the Reversal of Direct Oral Anticoagulants in Bleeding Patients.
Allison TA; Lin PJ; Gass JA; Chong K; Prater SJ; Escobar MA; Hartman HD
J Intensive Care Med; 2020 Sep; 35(9):903-908. PubMed ID: 30244638
[TBL] [Abstract][Full Text] [Related]
42. Practical management of bleeding in patients receiving non-vitamin K antagonist oral anticoagulants.
Weitz JI; Pollack CV
Thromb Haemost; 2015 Nov; 114(6):1113-26. PubMed ID: 26155974
[TBL] [Abstract][Full Text] [Related]
43. Four-factor prothrombin complex concentrate reverses apixaban-associated bleeding in a rabbit model of acute hemorrhage.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
J Thromb Haemost; 2015 Dec; 13(12):2220-6. PubMed ID: 26447393
[TBL] [Abstract][Full Text] [Related]
44. Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting.
Ghadimi K; Levy JH; Welsby IJ
Anesth Analg; 2016 May; 122(5):1287-300. PubMed ID: 26983050
[TBL] [Abstract][Full Text] [Related]
45. Contemporary Anticoagulation Reversal Focus on Direct Thrombin Inhibitors and Factor Xa Inhibitors.
Mancl EE; Crawford AN; Voils SA
J Pharm Pract; 2013 Feb; 26(1):43-51. PubMed ID: 23160865
[TBL] [Abstract][Full Text] [Related]
46. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
Larsen FU; Hvas AM; Grove EL
Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
[TBL] [Abstract][Full Text] [Related]
47. Heparin supplement counteracts the prohemostatic effect of prothrombin complex concentrate and factor IX concentrate: An in vitro evaluation.
Brinkman HJ; Patiwael S; Tripathi S; Meijers JC
Thromb Res; 2016 Mar; 139():102-10. PubMed ID: 26916304
[TBL] [Abstract][Full Text] [Related]
48. Reversal of target-specific oral anticoagulants.
Siegal DM; Cuker A
Drug Discov Today; 2014 Sep; 19(9):1465-70. PubMed ID: 24880102
[TBL] [Abstract][Full Text] [Related]
49. Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study.
Song Y; Wang Z; Perlstein I; Wang J; LaCreta F; Frost RJA; Frost C
J Thromb Haemost; 2017 Nov; 15(11):2125-2137. PubMed ID: 28846831
[TBL] [Abstract][Full Text] [Related]
50. The use of prothrombin complex concentrates in the treatment of hemorrhages induced by oral anticoagulation.
Pindur G; Mörsdorf S
Thromb Res; 1999 Aug; 95(4 Suppl 1):S57-61. PubMed ID: 10499910
[TBL] [Abstract][Full Text] [Related]
51. [Clinical perspectives on the management of bleeding in patients on oral anticoagulants: the DECOVER Study (DElphi Consensus on oral COagulation and therapy action reVERsal)].
Vicente V; Martín A; Lecumberri R; Coll-Vinent B; Suero C; González-Porras JR; Marco P; Mateo J; Roldán V; Soulard S; Crespo C; Camats M;
Emergencias; 2017 Feb; 29(1):18-26. PubMed ID: 28825264
[TBL] [Abstract][Full Text] [Related]
52. [Administration of a new prothrombin complex concentrate in patients treated with anticoagulants and in patients with liver diseases].
Fischer M; Falkensammer C; Gauss P; Korp W; Kubiena K; Neubert J; Schnack H; Weissmann A
Med Welt; 1973 Nov; 24(48):1899-902. PubMed ID: 4774863
[No Abstract] [Full Text] [Related]
53. [Attempted suicide with super warfarin].
Rodrigo Casanova P; Rodríguez Fernández V; García Peña JM; Aguilera Celorrio L
Rev Esp Anestesiol Reanim; 2005 Oct; 52(8):506-7. PubMed ID: 16281750
[No Abstract] [Full Text] [Related]
54. New oral anticoagulants: clinical indications, monitoring and treatment of acute bleeding complications.
Fenger-Eriksen C; Münster AM; Grove EL
Acta Anaesthesiol Scand; 2014 Jul; 58(6):651-9. PubMed ID: 24716468
[TBL] [Abstract][Full Text] [Related]
55. Managing target-specific oral anticoagulant associated bleeding including an update on pharmacological reversal agents.
Siegal DM
J Thromb Thrombolysis; 2015 Apr; 39(3):395-402. PubMed ID: 25586208
[TBL] [Abstract][Full Text] [Related]
56. Acute management of bleeding in patients on novel oral anticoagulants.
Siegal DM; Crowther MA
Eur Heart J; 2013 Feb; 34(7):489-498b. PubMed ID: 23220847
[TBL] [Abstract][Full Text] [Related]
57. Correlation of coagulation markers and 4F-PCC-mediated reversal of rivaroxaban in a rabbit model of acute bleeding.
Herzog E; Kaspereit F; Krege W; Mueller-Cohrs J; Doerr B; Niebl P; Dickneite G
Thromb Res; 2015 Mar; 135(3):554-60. PubMed ID: 25619440
[TBL] [Abstract][Full Text] [Related]
58. Human prothrombin complex.
N Engl J Med; 1965 Sep; 273(13):715-6. PubMed ID: 5827038
[No Abstract] [Full Text] [Related]
59. Prothrombin complex concentrate (Octaplex): a Portuguese experience in 1152 patients.
Carvalho MC; Rodrigues AG; Conceição LM; Galvão ML; Ribeiro LC
Blood Coagul Fibrinolysis; 2012 Apr; 23(3):222-8. PubMed ID: 22450543
[TBL] [Abstract][Full Text] [Related]
60. Reversal of new, factor-specific oral anticoagulants by rFVIIa, prothrombin complex concentrate and activated prothrombin complex concentrate: a review of animal and human studies.
Lee FM; Chan AK; Lau KK; Chan HH
Thromb Res; 2014 May; 133(5):705-13. PubMed ID: 24666649
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
